David Lockhart, ReCode Therapeutics CEO
Pfizer throws its weight behind LNP player eyeing mRNA treatments for CF, PCD
David Lockhart did not see the meteoric rise of messenger RNA and lipid nanoparticles coming.
Thanks to the worldwide fight against Covid-19, mRNA — the genetic code that can be engineered to turn the body into a mini protein factory — and LNPs, those tiny bubbles of fat carrying those instructions, have found their way into hundreds of millions of people. Within the biotech world, pioneers like Alnylam and Intellia have demonstrated just how versatile LNPs can be as a delivery vehicle for anything from siRNA to CRISPR/Cas9.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters